Jyong Biotech Signs MOU with Vietnamese Distributor to Explore MCS-2 Market Entry
核心洞察
Jyong Biotech Ltd. (搜索) has entered into a non-binding memorandum of understanding with a Vietnam-based pharmaceutical distribution company to evaluate the development and commercialization of MCS-2 in the Vietnamese market.
The MOU follows the company's previously announced letter of intent with a South Korean pharmaceutical company for plant-derived MCS products, demonstrating Jyong Biotech's Asia-focused expansion strategy.
MCS-2 remains an investigational new drug candidate that has not been approved for commercial use in any jurisdiction, with the companies proceeding to due diligence and discussions for potential collaboration.
Jyong Biotech Ltd. (搜索) (Nasdaq: MENS), a Taiwan-based biotechnology company specializing in plant-derived treatments for urinary system diseases (搜索), announced on December 4, 2025, that it has entered into a non-binding memorandum of understanding (MOU) with a Vietnam-based pharmaceutical distribution company headquartered in Ho Chi Minh City. The agreement aims to evaluate the development and commercialization of MCS-2 in the Vietnamese pharmaceutical market.
Partnership Structure and Next Steps
Under the terms of the MOU, Jyong Biotech and the Vietnamese pharmaceutical distribution company will proceed with due diligence and discussions to determine the scope and structure of any definitive collaboration. The evaluation will include commercial strategy, regulatory pathway, and local market execution considerations. The company noted that there can be no assurance that any definitive agreement will be reached or that any contemplated collaboration will be consummated.
Strategic Expansion in Asia
Fu Feng Kuo, CEO and Chairwoman of Jyong Biotech, commented on the significance of this partnership: "This MOU represents an important step in our Asia-focused strategy to bring plant-derived MCS therapies to new markets. Vietnam presents meaningful opportunities for patient access and local partnership, and we are committed to working closely with our prospective partner to evaluate viable regulatory and commercial pathways while safeguarding the scientific and clinical integrity of MCS-2."
The Vietnamese MOU follows Jyong Biotech's previously announced non-binding Letter of Intent with a South Korean pharmaceutical company to evaluate in-licensing and development opportunities for plant-derived MCS products, which was announced on November 24, 2025.
Regulatory Status and Company Background
MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech has committed to complying with applicable regulatory disclosure obligations and providing timely, accurate, and complete updates on material developments.
Founded in 2002 and headquartered in Taiwan, Jyong Biotech is a science-driven biotechnology company committed to developing and commercializing innovative plant-derived drugs, with a primary focus on treating urinary system diseases (搜索). The company targets markets in the U.S., the EU, and Asia. Since its inception, Jyong Biotech has built integrated capabilities encompassing all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization.
The company's pipeline includes its primary botanical drug candidate BOTRESO® (搜索), another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates, all developed through its proprietary platform and strong research and development capabilities.